A Study of the Safety, Tolerability, Pharmacokinetics and Food Effect After Single and Multiple Ascending Oral Doses

June 27, 2023 updated by: Artax Biopharma Inc

A Randomised, Double-blind, Placebo-controlled, Study of the Safety, Tolerability, and Pharmacokinetics of AX-158 Following Administration of Single and, Multiple Ascending Oral Doses and Food Effect Sub-study in Healthy Male Volunteers

This is a Phase I Healthy volunteer study with the primary objective to evaluate the safety and pharmacokinetics profile of AX-158. The first part will evaluate single ascending dose administrations. A substudy will be performed as well to evaluate possible impact of food on drug exposure if administered under fasted or fed state. The second part will evaluate multiple ascending dose over 10 days of dosing in fed or fast state depending on the results of the substudy food effect on AX-158.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This is a phase I, randomised, double-blind , placebo controlled study to investigate the safety, tolerability, and PK of AX-158 in healthy male participants following single (Part A) and multiple (Part C) ascending doses including food effect (Part B).The study will be conducted in three parts (Part A, Part B and Part C). Part A will enrol 8 participants per cohort randomised (3 :1) to receive AX-158 (6 participants) or placebo (2 participants). Part A will follow a single ascending dose (SAD) design with all participants receiving one dose of AX-158 (or placebo) in the fasted state. Part B (Food Effect) will be conducted in 8 participants in a cross-over manner; each participant will receive AX-158 in the fed and fasted state. Part C will enrol 8 participants per cohort randomised to (3 :1) to receive AX-158 (6 participants) or placebo (2 participants). Part C will follow a multiple ascending dose (MAD) design with participants receiving AX-158 (or placebo) once daily for 10 consecutive days, in a fed or fasted state (depending on the outcome of the Part B (Food Effect).

Study Type

Interventional

Enrollment (Actual)

64

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 48 years (Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  1. Healthy Male participant, between 18 and 50 years of age, inclusive.
  2. Male participant (and partner of childbearing potential) willing to use a highly effective method of contraception in addition to a condom, if applicable (unless anatomically sterile or where abstaining from sexual intercourse is in line with the preferred and usual lifestyle of the participant) from first dose until 4 months after last dose of Investigational Medicinal Product (IMP).
  3. Participant with a body mass index (BMI) of 18-30kg/m2. BMI = body weight (kg) / [height (m)]2.
  4. Total serum bilirubin, alkaline phosphatase (ALP), aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 1.5 x upper limit of normal (ULN). If total bilirubin is above the upper limit of normal and is then fractionated, direct bilirubin must be within normal limits.
  5. Total serum Testosterone levels 2 x above the lower limit of the normal range within 28 days before the first dose administration of the IMP.
  6. Participant with a negative urinary drugs of abuse (DOA) screen (including alcohol) test results, determined within 28 days before the first dose administration of the IMP (N.B.: A positive test result may be repeated at the Investigator's discretion).
  7. Participant with negative human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg)) and hepatitis C virus antibody (HCV Ab) test results at Screening.
  8. No clinically significant abnormalities in 12-lead electrocardiogram (ECG) determined within 28 days before first dose of IMP including a QRS interval > 120ms, PR interval > 220ms and QTcF > 450ms.
  9. No clinically significant abnormalities in vital signs (e.g., blood pressure/pulse rate, respiration rate and oral temperature) determined within 28 days before first dose of IMP.
  10. Participant must be available to complete the study (including all follow-up visits).
  11. Participant must satisfy an Investigator about his fitness to participate in the study.
  12. Participant must provide written informed consent to participate in the study.
  13. Participants with a negative COVID-19 PCR test on admission.

Exclusion Criteria:

  1. A clinically significant history of gastrointestinal disorder likely to influence IMP absorption.
  2. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 28 days or 5 half-lives (whichever is longer) prior to the first dose of IMP. Occasional use of paracetamol will be allowed.
  3. Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular, or metabolic dysfunction.
  4. Clinically significant history of previous allergy / sensitivity to AX-158 or any of the excipients contained within the IMP.
  5. Participant with history of autoimmune disease, cardiac disease, kidney disease or any food intolerance.
  6. Participants with clinically significant abnormal test results for serum biochemistry, haematology and/or urine analyses within 28 days before the first dose administration of the IMP
  7. A clinically significant history of drug or alcohol abuse (defined as the consumption of more than 14 units [for male and female participants] of alcohol a week) within the past two years.
  8. Inability to communicate well with the Investigators (i.e., language problem, poor mental development, or impaired cerebral function).
  9. Participation in a New Chemical Entity (NCE) clinical study within the previous 3 months or five half-lives, whichever is longer, or a marketed drug clinical study within the 30 days or five half-lives, whichever is longer, before the first dose of IMP. (Washout period between studies is defined as the period of time elapsed between the last dose of the previous study and the first dose of the next study).
  10. Donation of 450 milliliters or more blood within the 3 months before the first dose of IMP.
  11. Vegans, vegetarians, or other dietary restrictions (e.g., restrictions for medical, religious, or cultural reasons, etc), which would prevent participants from consuming a high-fat breakfast or standardised meal.
  12. Users of nicotine products i.e., current smokers or ex-smokers who have smoked within the 6 months prior to screening or users of cigarette replacements (i.e., e-cigarettes, nicotine patches or gums).
  13. Participants who have received a COVID-19 vaccine injection within 28 days prior to the first dose of IMP.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Part A-Drug (AX-158 or Placebo)
AX-158 oral single or placebo (single ascending dose).
Drug: AX-158
Oral administrations of AX-158
Other Names:
  • Placebo
Experimental: Part B-Drug (AX-158)
AX-158 oral single dose with and without food
Drug: AX-158
Oral administrations of AX-158
Other Names:
  • Placebo
Experimental: Part C-Drug (AX-158 and Placebo)
AX-158 oral or placebo daily dose for 10 days (multiple ascending dose).
Drug: AX-158
Oral administrations of AX-158
Other Names:
  • Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of Treatment-Emergent Adverse Events
Time Frame: Up to 10 days of treatment
The number and severity of adverse events that can be related to treatment with single and multiple doses of ARTAX
Up to 10 days of treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The pharmacokinetics (PK) of single and multiple dose administration of ARTAX in volunteers
Time Frame: Up to 10 days
Maximal plasma concentration (Cmax)
Up to 10 days
Total Plasma Drug Exposure of a single and multiple dose administration of ARTAX in volunteers
Time Frame: Up to 10 days
Measurement of the area under the curve (AUC) at day 1 and day 10 in plasma
Up to 10 days
Comparison of the single dose and multiple dose elimination of ARTAX
Time Frame: Up to 10 days
Determination of the half-life (T1/2) for single and multiple doses of ARTAX
Up to 10 days
Total Plasma Drug Exposure of single dose administration of ARTAX under fasting and fed conditions in volunteers
Time Frame: Three days
Measurement of the area under the curve (AUC) after single dose administration of ARTAX after an overnight fast or after a high fat breakfast
Three days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Artax Biopharma Inc

Collaborators

Simbec-Orion Group

Investigators

  • Principal Investigator: Dr Annelize Koch, Simbec-Orion Merthyr Tydfil CF48 4DR, United Kingdom

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 17, 2021

Primary Completion (Actual)

November 16, 2022

Study Completion (Actual)

December 3, 2022

Study Registration Dates

First Submitted

December 2, 2021

First Submitted That Met QC Criteria

January 17, 2022

First Posted (Actual)

February 1, 2022

Study Record Updates

Last Update Posted (Actual)

June 28, 2023

Last Update Submitted That Met QC Criteria

June 27, 2023

Last Verified

June 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • AX-158-101

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Autoimmune Diseases

Clinical Trials on AX-158

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ukraine

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe